Black Diamond Therapeutics Soars on Positive Clinical Updates and Licensing Deal

Black Diamond Therapeutics shares are trading higher after the company reported promising advancements in their Phase 2 trial for BDTX-1535 and announced a lucrative global licensing agreement with Servier for BDTX-4933.